Contents

Series Foreword ix
Preface xi
Acknowledgements xiii
Abbreviations xv
Introduction xxi

1 Drug Life Cycle 1
1.1 Introduction 1
1.2 Drivers of the search for a new drug 2
    1.2.1 Strategic criteria 3
    1.2.2 Scientific and technical criteria 3
    1.2.3 Operational criteria 4
1.3 Structure of a drug life cycle 5
1.4 Costs and risks of drug research and development 6
    1.4.1 Cost drivers 6
    1.4.2 Estimates of drug development costs 7
1.5 Risks of drug R&D 7
    1.5.1 Failure and success rates in drug development 7
    1.5.2 Net present value 8
1.6 Value for patient and society 9
1.7 The end of a drug’s life 9
1.8 Management 10
References 10

2 Drug Discovery and Design 13
2.1 Introduction 13
2.2 Approaches in drug discovery 14
    2.2.1 Phenotypic based 14
    2.2.2 Target based 14
    2.2.3 Molecular drug design 15
CONTENTS

2.3 The drug discovery process 16
  2.3.1 Exploratory phase 17
  2.3.2 Assay development 17
  2.3.3 Screening 18
  2.3.4 Hit-to-lead 18
  2.3.5 Lead optimisation 19

References 21

3 Drug Development: General Aspects 23
  3.1 Introduction 23
  3.2 The objective of drug development 23
  3.3 Drug development organisations and teams 24
  3.4 Drug development streams
    3.4.1 Chemical and pharmaceutical development 27
    3.4.2 Nonclinical development 31
    3.4.3 Clinical development 33
    3.4.4 Interaction between the development streams 35
  3.5 Phases in drug development
    3.5.1 Early development 36
    3.5.2 Late development 38
    3.5.3 Milestones in drug development 38
  3.6 Regulatory environment
    3.6.1 Legislation and guidelines 44
    3.6.2 Regulatory authorities and organisations 45
    3.6.3 Regulatory processes and documents 48
  3.7 Quality management
    3.7.1 General principles 58
    3.7.2 Good Practices 59
    3.7.3 Standard Operating Procedures (SOP) 69
    3.7.4 Quality control 70
    3.7.5 Audits and inspections 71
    3.7.6 Quality risk management 73
  3.8 Project risk management 75
    3.8.1 Nature of risk 75
    3.8.2 Types of risk 76
    3.8.3 Analysis of risk and ‘show stoppers’ 77
  3.9 Ethical considerations 78
    3.9.1 General aspects 79
    3.9.2 Use of experimental animals 80
    3.9.3 Experiments involving human subjects 82
  3.10 The global nature of drug development 87

References 89

4 Methods and Techniques Used in Drug Development 91
  4.1 Introduction 91
  4.2 Chemical and pharmaceutical development
    4.2.1 Physicochemical characterisation of the active ingredient 92
    4.2.2 Formulation of the active ingredient 94
    4.2.3 Determination of the quality of the active ingredient and the drug product 99
  4.3 Nonclinical development
    4.3.1 Pharmacokinetics 106
    4.3.2 Safety pharmacology 119
    4.3.3 Toxicology 125
CONTENTS

4.4 Clinical development 139
  4.4.1 Pharmacometrics 139
  4.4.2 Biomarkers 140
  4.4.3 Imaging techniques 142
  4.4.4 Human electrocardiography 146
  4.4.5 Clinical trial methodology 147
  4.4.6 Organisational challenges in clinical drug trials 163
References 166

5 The Early Development of a New Drug 169
  5.1 Introduction 169
  5.2 Pre-clinical phase 170
    5.2.1 Chemical and pharmaceutical development 170
    5.2.2 Nonclinical development 180
    5.2.3 Clinical development 190
    5.2.4 Integration and decision making 196
  5.3 Clinical phase 200
    5.3.1 Chemical and pharmaceutical development 201
    5.3.2 Nonclinical development 215
    5.3.3 Clinical development 226
    5.3.4 Integration and decision making 250
References 251

6 The Late Development of a New Drug 253
  6.1 Introduction 253
  6.2 Pre-approval development 254
    6.2.1 Chemical and pharmaceutical development 254
    6.2.2 Nonclinical development 282
    6.2.3 Clinical development 297
    6.2.4 Integration and decision making 311
  6.3 Marketing authorisation 316
    6.3.1 Marketing authorisation procedures 316
    6.3.2 Granting of marketing authorisation 325
    6.3.3 Compassionate use and medical need programmes 326
    6.3.4 Market access 327
  6.4 Post-approval development 328
    6.4.1 Chemical and pharmaceutical development 328
    6.4.2 Nonclinical development 329
    6.4.3 Clinical development 333
    6.4.4 Integration and decision making 345
References 347

7 Special Drug Developments 351
  7.1 Introduction 351
  7.2 Development of orphan drugs 351
  7.3 Paediatric drug development 354
    7.3.1 PK-based dose selection 355
    7.3.2 Clinical trial-based dose selection 356
  7.4 Geriatric drug development 356
  7.5 Development of fixed-dose drug combinations 358
  7.6 Other special drug developments 360
References 360
CONTENTS

8 Drug Commercialisation 361
8.1 Introduction 361
8.2 Market access 363
  8.2.1 Drug pricing 363
  8.2.2 Drug reimbursement 364
  8.2.3 Additional hurdles 369
8.3 Pharmaceutical marketing 370
  8.3.1 The pharmaceutical market 370
  8.3.2 General marketing principles 372
  8.3.3 Pharmaceutical marketing activities 374
  8.3.4 Drug promotion regulation 381
8.4 Independent drug information 382
8.5 Rational use of medicines 383
References 384

Epilogue 387

Index 391